1Zager RA,Johnson AC,Hanson SY.Radiographic contrast media-induced tubular injury:evaluation of oxidant stress and plasma membrane integrity[J].Kidney Int,2003,64(1):128-139.
2Alonso A,Lau J,Jaber BL,et al.Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease:a meta-analysis of randomizes,controlled trials[J].Am J Kidney Dis,2004,43(1):1-9.
3Isenbarger DW,Kent SM,O'Malley PG.Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy[J].Am J Cardiol,2003;92(12):1454-1458.
4Birck R,Krzossok S,Markowetz F,et al.Acetylchsteine for prevention of contrast nephropathy:meta analysis[J].Lancet,2003,362(9384):598-603.
5Briguori C,Colombo A,Violante A,et al.Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity[J].Eur Heart J,2004,25(3):206-211.
6Goldenberg I,Shechter M,Matetzky S,et al.Oral acetylcysteine as an adjunt to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography.A randomized controlled trial and review of the current literature[J].Eur Heart J,2004,25(3):212-218.
7Esnault VL.Radiocontrast media-induced nephrotoxicity in patients with renal failure:rationale for a new double-blind,prospective,randomized trial testing calcium channel antagonists[J].Nephrol Dial Transplant,2002,17(8):1362-1364.
8Oldroyd SD,Morcos SK.Endothelin:what does the radiologist need to know?[J].Br J Radiol,2000,73(876):1246-1251.
9Wang A,Holcslow T,Bashore TM,et al.Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism[J].Kidney Int,2000,57(4):1675-1680.
10Kini AS,Mitre CA,Kamran M,et al.Changing trends in incidence and percutaneous coronary intervention with use of fenoldopam[J],2002,89(8):999-1002.
